Status:
COMPLETED
SARCOTHAL. Thalidomide in Skin Sarcoidosis
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Sarcoidosis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Sarcoidosis is a multisystem disease involving most frequently the lung, the eyes, the lymph nodes and the skin. Skin lesions may be disfiguring and impair the quality of life. Thalidomide is a multi-...
Detailed Description
The study consists in comparing thalidomide to placebo in skin sarcoidosis. Patients with sarcoidosis not necessitating a high-dose corticosteroid regimen, and assessable skin lesions, are eligible. T...
Eligibility Criteria
Inclusion
- Biopsy proven skin sarcoidosis
- Assessable target skin lesions
Exclusion
- Rapidly evolving sarcoidosis
- Patients necessitating a corticosteroid regimen of more than 15mg per day.
- Women not willing to undertake a contraceptive method.
- Neurologic impairment
- Past treatment with Thalidomide
- Renal impairment
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00305552
Start Date
February 1 2005
End Date
November 1 2007
Last Update
May 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HOPITAL Saint Louis, Service de Dermatologie
Paris, France, 75010